UniCAR T cell immunotherapy enables efficient elimination of radioresistant cancer cells.
CD98
EGFR
T cell immunotherapy
adaptor CAR
radioresistance
Journal
Oncoimmunology
ISSN: 2162-4011
Titre abrégé: Oncoimmunology
Pays: United States
ID NLM: 101570526
Informations de publication
Date de publication:
2020
2020
Historique:
received:
13
12
2019
revised:
14
01
2020
accepted:
15
01
2020
entrez:
20
5
2020
pubmed:
20
5
2020
medline:
20
5
2020
Statut:
epublish
Résumé
Induction or selection of radioresistant cancer (stem) cells following standard radiotherapy is presumably one of the major causes for recurrence of metastatic disease. One possibility to prevent tumor relapse is the application of targeted immunotherapies including, e.g., chimeric antigen receptor (CAR) T cells. In light of long-term remissions, it is highly relevant to clarify whether radioresistant cancer cells are susceptible to CAR T cell-mediated killing. To answer this question, we evaluated the anti-tumor activity of the switchable universal chimeric antigen receptor (UniCAR) system against highly radioresistant head and neck squamous cell carcinoma cells both
Identifiants
pubmed: 32426176
doi: 10.1080/2162402X.2020.1743036
pii: 1743036
pmc: PMC7219270
doi:
Substances chimiques
Receptors, Chimeric Antigen
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
1743036Informations de copyright
© 2020 The Author(s). Published with license by Taylor & Francis Group, LLC.
Références
Clin Cancer Res. 2019 May 15;25(10):3152-3163
pubmed: 30670494
J Immunol. 1981 Apr;126(4):1409-14
pubmed: 7204970
Oncotarget. 2018 May 22;9(39):25597-25616
pubmed: 29876011
J Cell Sci. 2012 Mar 15;125(Pt 6):1373-82
pubmed: 22499670
Cancer Immunol Immunother. 2019 Oct;68(10):1713-1719
pubmed: 31542798
Immunol Lett. 2019 Jul;211:13-22
pubmed: 31091431
Int J Radiat Oncol Biol Phys. 1994 May 15;29(2):243-7
pubmed: 8195014
J Immunol. 2012 Sep 15;189(6):3249-59
pubmed: 22875801
Oncotarget. 2017 May 9;8(19):31368-31385
pubmed: 28404896
Cancers (Basel). 2019 Jun 21;11(6):
pubmed: 31234336
PLoS One. 2014 Apr 03;9(4):e93745
pubmed: 24699869
Clin Transl Radiat Oncol. 2017 Feb 04;2:29-35
pubmed: 29657997
N Engl J Med. 2006 Feb 9;354(6):567-78
pubmed: 16467544
Blood. 2014 Jan 16;123(3):356-65
pubmed: 24300852
J Biomed Biotechnol. 2010;2010:956304
pubmed: 20467460
J Autoimmun. 2013 May;42:105-16
pubmed: 23352111
Mol Ther. 2018 Nov 7;26(11):2542-2552
pubmed: 30415658
Br J Haematol. 2019 Sep;186(5):735-740
pubmed: 31119728
Lancet Oncol. 2019 Aug;20(8):e443-e451
pubmed: 31364596
Stem Cell Res. 2013 May;10(3):477-88
pubmed: 23523931
N Engl J Med. 2018 Jul 5;379(1):64-73
pubmed: 29972754
Blood Cancer J. 2018 Aug 22;8(9):81
pubmed: 30190468
Methods. 2005 May;36(1):3-10
pubmed: 15848070
Clin Cancer Res. 2019 Mar 15;25(6):1702-1708
pubmed: 30413526
J Autoimmun. 2018 Jun;90:116-131
pubmed: 29503042
Cancer Res. 2012 Apr 1;72(7):1844-52
pubmed: 22315351
Pharmacol Res. 2014 Jan;79:34-74
pubmed: 24269963
Cancer Res. 2002 Dec 15;62(24):7350-6
pubmed: 12499279
Oncotarget. 2017 Sep 18;8(65):108584-108603
pubmed: 29312553
J Am Chem Soc. 2015 Mar 4;137(8):2832-5
pubmed: 25692571
Lancet Oncol. 2010 Jan;11(1):21-8
pubmed: 19897418
Int J Radiat Oncol Biol Phys. 2003 Sep 1;57(1):246-54
pubmed: 12909240
Nat Rev Cancer. 2016 Apr;16(4):234-49
pubmed: 27009394
Int J Mol Sci. 2016 Jan 14;17(1):
pubmed: 26784176
Front Immunol. 2019 Jul 16;10:1613
pubmed: 31379824
Int J Biochem Cell Biol. 2015 Oct;67:25-33
pubmed: 26256001
Blood Rev. 2016 May;30(3):157-67
pubmed: 26574053
Cancer Res. 2018 Feb 15;78(4):1031-1043
pubmed: 29222400
Curr Opin Hematol. 2019 Nov;26(6):427-433
pubmed: 31577606
Prostate. 2014 Sep;74(13):1347-58
pubmed: 25053504
Cancer Chemother Pharmacol. 2014 Jun;73(6):1227-39
pubmed: 24714973
Semin Radiat Oncol. 2018 Jan;28(1):12-16
pubmed: 29173750
Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):959-65
pubmed: 14967456
Leukemia. 2014 Jan;28(1):59-69
pubmed: 23958923
Int J Radiat Oncol Biol Phys. 2004 Feb 1;58(2):561-6
pubmed: 14751528
Cancer Manag Res. 2017 Aug 18;9:363-371
pubmed: 28860859
Cancer Immunol Immunother. 2019 Sep;68(9):1401-1415
pubmed: 31414180
Oncoimmunology. 2017 Feb 6;6(4):e1287246
pubmed: 28507794
Drug Discov Today. 2018 Jun;23(6):1175-1182
pubmed: 29501911
Oncotarget. 2017 Dec 21;9(7):7487-7500
pubmed: 29484126
Proc Natl Acad Sci U S A. 2016 Jan 26;113(4):E459-68
pubmed: 26759369
Blood Cancer J. 2016 Aug 12;6(8):e458
pubmed: 27518241
Nat Rev Clin Oncol. 2018 Jan;15(1):47-62
pubmed: 28925994
Transl Lung Cancer Res. 2017 Apr;6(2):159-168
pubmed: 28529898
J Adv Pract Oncol. 2018 Jul-Aug;9(5):537-544
pubmed: 31086690
J Natl Cancer Inst. 1998 Jun 3;90(11):824-32
pubmed: 9625170
Mol Immunol. 2011 Dec;49(3):474-82
pubmed: 22014687
Prostate. 2011 Jun 15;71(9):998-1011
pubmed: 21541976
Sci Rep. 2019 Jul 22;9(1):10547
pubmed: 31332252
Methods Mol Biol. 2018;1853:27-30
pubmed: 30097926
Oncotarget. 2015 Oct 27;6(33):34494-509
pubmed: 26460734
Oncoimmunology. 2019 Sep 7;8(11):1659095
pubmed: 31646084
Proc Natl Acad Sci U S A. 2014 Feb 25;111(8):2966-71
pubmed: 24516142
J Labelled Comp Radiopharm. 2019 Jun 30;62(8):533-540
pubmed: 30889625